Warren Buffett Detailed Fundamental Analysis

According to Validea's guru fundamental report, Accenture PLC (ACN) receives an 86% rating based on their Patient Investor model, which is based on Warren Buffett's published investment strategy; a score above 80% typically indicates the strategy has some interest in the stock. The model favors firms with predictable profitability, low debt, and reasonable valuations, all of which ACN currently exhibits based on underlying fundamentals.

Analysis

Accenture PLC (ACN) has garnered a notable 86% rating from Validea's Patient Investor model, which is benchmarked against Warren Buffett's investment tenets, indicating a significant level of strategic interest as scores above 80% are considered noteworthy. This model specifically targets firms with long-term, predictable profitability, low debt, and reasonable valuations. The report confirms that ACN, a large-cap growth stock within the Computer Services industry, successfully passes all nine fundamental criteria evaluated by this strategy: Earnings Predictability, Debt Service, Return on Equity, Return on Total Capital, Free Cash Flow, Use of Retained Earnings, Share Repurchase, Initial Rate of Return, and Expected Return. This comprehensive positive assessment of ACN's underlying fundamentals and stock valuation, supported by a per-ticker sentiment score of 0.85, underscores its strong financial health and alignment with value-oriented growth principles.

Key Decisions for Investors

• Given ACN's 86% score on Validea's Patient Investor model and its adherence to all key fundamental criteria, investors might consider it a strong candidate for long-term portfolios focused on quality growth.
• The consistent positive performance across metrics like earnings predictability, low debt, and return on capital suggests further due diligence is warranted for potential inclusion in investment strategies aligned with Buffett-style principles.
• Investors should continue to monitor ACN's valuation to ensure it remains reasonable, as this is a crucial element of the Patient Investor strategy's positive assessment.